MA49744A - Méthodes de traitement de l'oesophagite à éosinophiles active - Google Patents

Méthodes de traitement de l'oesophagite à éosinophiles active

Info

Publication number
MA49744A
MA49744A MA049744A MA49744A MA49744A MA 49744 A MA49744 A MA 49744A MA 049744 A MA049744 A MA 049744A MA 49744 A MA49744 A MA 49744A MA 49744 A MA49744 A MA 49744A
Authority
MA
Morocco
Prior art keywords
treatment methods
eosinophilic esophagitis
active eosinophilic
active
esophagitis
Prior art date
Application number
MA049744A
Other languages
English (en)
French (fr)
Inventor
Jennifer D Hamilton
Leda Mannent
Allen Radin
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA49744A publication Critical patent/MA49744A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA049744A 2017-08-04 2018-08-03 Méthodes de traitement de l'oesophagite à éosinophiles active MA49744A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US201762561593P 2017-09-21 2017-09-21
EP18305252 2018-03-08

Publications (1)

Publication Number Publication Date
MA49744A true MA49744A (fr) 2020-06-10

Family

ID=63113646

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049744A MA49744A (fr) 2017-08-04 2018-08-03 Méthodes de traitement de l'oesophagite à éosinophiles active

Country Status (9)

Country Link
EP (1) EP3661551A1 (enExample)
JP (2) JP7417515B2 (enExample)
KR (2) KR20240152980A (enExample)
CN (1) CN111032084A (enExample)
AU (2) AU2018311981B2 (enExample)
CA (1) CA3071528A1 (enExample)
IL (2) IL315556A (enExample)
MA (1) MA49744A (enExample)
MX (2) MX2020001305A (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250154267A2 (en) * 2020-05-22 2025-05-15 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
IL316470A (en) * 2022-04-29 2024-12-01 Akeso Biopharma Inc Anti-human il-4ra antibody and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
AU2016231122A1 (en) * 2015-03-11 2017-09-07 Glaxosmithkline Intellectual Property Development Limited TSLP binding proteins

Also Published As

Publication number Publication date
MX2024012777A (es) 2024-11-08
KR20240152980A (ko) 2024-10-22
AU2025200955A1 (en) 2025-03-06
JP2020529434A (ja) 2020-10-08
EP3661551A1 (en) 2020-06-10
KR20200035442A (ko) 2020-04-03
AU2018311981A1 (en) 2020-02-20
RU2020109331A3 (enExample) 2021-12-28
IL315556A (en) 2024-11-01
IL272245B2 (en) 2025-02-01
JP2024016237A (ja) 2024-02-06
AU2018311981B2 (en) 2024-11-14
MX2020001305A (es) 2020-03-09
IL272245A (en) 2020-03-31
IL272245B1 (en) 2024-10-01
RU2020109331A (ru) 2021-09-06
CA3071528A1 (en) 2019-02-07
JP7417515B2 (ja) 2024-01-18
KR102719720B1 (ko) 2024-10-22
CN111032084A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
EP3813808A4 (en) Methods of treating substance abuse
MA45192A (fr) Traitement d'association
EP3490582A4 (en) METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE
IL261935A (en) Methods of treatment of cholestatic diseases
EP3458589A4 (en) COMPOSITIONS AND METHODS FOR TREATING MORBUS HUNTINGTON
DK3516060T3 (da) Antisense-oligonukleotider til behandling af øjensygdom
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA46062A (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
DK3364997T5 (da) Aspartoacylase genterapi til behandling af canavans sygdom
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3684418A4 (en) METHOD FOR TREATMENT OF CYSTEAMINE SENSITIVE DISEASES
EP3706737A4 (en) ASH11 INHIBITORS AND METHOD OF TREATING THEREOF
EP3340971A4 (en) METHOD FOR TREATING LENNOX-GASTAUT SYNDROME WITH FENFLURAMINE
EP3298140A4 (en) COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CALCIFICATION DISEASES AND METHODS OF USE THEREOF
EP3409744A4 (en) SURFACE TREATMENT AGENT
EP3625971A4 (en) SPATIAL AUDIO PROCESSING
EP3285776A4 (en) METHOD FOR TREATING BACTERIAL INFECTIONS
EP3858943A4 (en) Surface treatment agent
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
EP3431566A4 (en) SURFACE TREATMENT AGENT
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
EP3751048A4 (en) FIBER TREATMENT AGENT
EP3468548A4 (en) METHOD FOR THE TREATMENT OF LATIVAL CANCER
EP3630101A4 (en) METHODS OF TREATMENT OF FIBROTIC DISEASES